TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Researchers from INSERM report on findings in life sciences
September 9th, 2008
A report, 'Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management,' is newly published data in Drug and Alcohol Dependence. "Though the introduction of office-based buprenorphine has greatly contributed to stem the HIV epidemic since 1995, concerns have been raised about the intravenous use of buprenorphine even in patients on substitution treatment. The aim of this study was to identify which factors are predictive of buprenorphine injection in patients receiving office-based buprenorphine," scientists in Marseille, France report. "Subazur is a survey consisting of two longitudinal assessments of 111...
Source: TB & Outbreaks Week (2008-09-09)
|
